The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis

被引:45
作者
Caramelo, Olga [1 ]
Silva, Cristina [2 ]
Caramelo, Francisco [3 ]
Frutuoso, Cristina [1 ]
Almeida-Santos, Teresa [4 ,5 ]
机构
[1] Coimbra Hosp & Univ Ctr, Gynecol Dept, EPE, P-3000075 Coimbra, Portugal
[2] Univ Coimbra, Fac Pharm, Rua Filipe Simoes 33, P-3000186 Coimbra, Portugal
[3] Univ Coimbra, Fac Med, Lab Biostat & Med Informat, iCBR, P-3000354 Coimbra, Portugal
[4] Coimbra Hosp & Univ Ctr, Human Reprod Dept, Ctr Fertil Preservat, EPE, P-3000075 Coimbra, Portugal
[5] Univ Coimbra, Fac Med, P-3000548 Coimbra, Portugal
关键词
Triple negative breast cancer; BRCA; Neoadjuvant chemotherapy; Cisplatin; Carboplatin; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II; CARBOPLATIN; THERAPY; WOMEN; CYCLOPHOSPHAMIDE; MUTATIONS; TNBC; GEPARSIXTO; PREVALENCE;
D O I
10.1186/s13053-019-0111-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTriple negative breast cancers (TNBC) are associated with an aggressive clinical course, earlier recurrence and short survival. BRCA - mutated tumours represent up to 25% of all TNBC. BRCA status is being studied as a predictive biomarker of response to platinum agents. However, the predictive role of BRCA status is still uncertain in this setting. Since TNBC is a very heterogeneous group of diseases, it is important to identify subsets of TNBC patients that may benefit from platinum-based therapy. This study aims to establish if the presence of a germline BRCA mutation in women with TNBC improves the pathologic complete response (pCR) after neoadjuvant chemotherapy with platinum compounds.MethodsAn extensive literature search was performed in MEDLINE, EMBASE and LILACS databases, WHO (WHO International Clinical Trials Registry Platform) and the Cochrane Controlled Trials Register Database, for online trial registries and conference proceedings. The measurement of pCR was assessed by pathology review of breast specimen and lymph nodes.ResultsThe overall OR was computed using random effects models.Seven studies were included, comprising a total of 808 TNBC patients, among which 159 were BRCA mutated. Among mutated TNBC patients, 93 (93/159; 58.4%) achieved pCR, while 410 wildtype patients (410/808; 50.7%) showed pCR (OR 1.459 CI 95% [0.953-2.34] p=0.082) although this result did not reach statistical significance.ConclusionsThis meta-analysis shows that the addition of platinum to chemotherapy regimens in the neoadjuvant setting increases pCR rate in BRCA - mutated as compared to wild-type TNBC patients. However, this trend did not achieve statistical significance.Trial registrationCRD42018092341
引用
收藏
页数:10
相关论文
共 46 条
[11]   Triple-negative breast cancer: Clinical features and patterns of recurrence [J].
Dent, Rebecca ;
Trudeau, Maureen ;
Pritchard, Kathleen I. ;
Hanna, Wedad M. ;
Kahn, Harriet K. ;
Sawka, Carol A. ;
Lickley, Lavina A. ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434
[12]   Pattern of metastatic spread in triple-negative breast cancer [J].
Dent, Rebecca ;
Hanna, Wedad M. ;
Trudeau, Maureen ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :423-428
[13]   Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years [J].
Dolle, Jessica M. ;
Daling, Janet R. ;
White, Emily ;
Brinton, Louise A. ;
Doody, David R. ;
Porter, Peggy L. ;
Malone, Kathleen E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (04) :1157-1166
[14]   PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. [J].
Earl, Helena Margaret ;
Vallier, Anne-Laure ;
Qian, Wendi ;
Grybowicz, Louise ;
Thomas, Stanly ;
Mahmud, Saba ;
Harvey, Caron ;
McAdam, Karen ;
Hughes-Davies, Luke ;
Roylance, Rebecca ;
Copson, Ellen ;
Brown, Jessica ;
Provenzano, Elena ;
McMurtry, Emma ;
Tischkowitz, Marc ;
Abraham, Jean .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[15]  
Fontaine C, 2017, ANN ONCOL, V28
[16]   Role of different germline BRCA mutations in response to platinum-based chemotherapy in patients (pts) with triple-negative breast cancer (TNBC). [J].
Frolova, Mona ;
Ignatova, Ekaterina ;
Stenina, Marina B. ;
Petrovsky, Alexander ;
Tjulandin, Sergei .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[17]   Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results [J].
Gluz, Oleg ;
Nitz, Ulrike ;
Liedtke, Cornelia ;
Christgen, Matthias ;
Grischke, Eva-Maria ;
Forstbauer, Helmut ;
Braun, Michael ;
Warm, Mathias ;
Hackmann, John ;
Uleer, Christoph ;
Aktas, Bahriye ;
Schumacher, Claudia ;
Bangemann, Nikola ;
Lindner, Christoph ;
Kuemmel, Sherko ;
Clemens, Michael ;
Potenberg, Jochem ;
Staib, Peter ;
Kohls, Andreas ;
von Schumann, Raquel ;
Harbeck, Nadia .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (06) :628-637
[18]   Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort [J].
Greenup, Rachel ;
Buchanan, Adam ;
Lorizio, Wendy ;
Rhoads, Keelia ;
Chan, Salina ;
Leedom, Tracey ;
King, Robin ;
McLennan, Jane ;
Crawford, Beth ;
Marcom, P. Kelly ;
Hwang, E. Shelley .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (10) :3254-3258
[19]   Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials [J].
Guan, Xiuwen ;
Ma, Fei ;
Fan, Ying ;
Zhu, Wenjie ;
Hong, Ruoxi ;
Xu, Binghe .
ANTI-CANCER DRUGS, 2015, 26 (08) :894-901
[20]   Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial [J].
Hahnen, Eric ;
Lederer, Bianca ;
Hauke, Jan ;
Loibl, Sibylle ;
Kroeber, Sandra ;
Schneeweiss, Andreas ;
Denkert, Carsten ;
Fasching, Peter A. ;
Blohmer, Jens U. ;
Jackisch, Christian ;
Paepke, Stefan ;
Gerber, Bernd ;
Kuemmel, Sherko ;
Schem, Christian ;
Neidhardt, Guido ;
Huober, Jens ;
Rhiem, Kerstin ;
Costa, Serban ;
Altmueller, Janine ;
Hanusch, Claus ;
Thiele, Holger ;
Mueller, Volkmar ;
Nuernberg, Peter ;
Karn, Thomas ;
Nekljudova, Valentina ;
Untch, Michael ;
von Minckwitz, Gunter ;
Schmutzler, Rita K. .
JAMA ONCOLOGY, 2017, 3 (10) :1378-1385